Introduction
The first suggestion of adaptive immune activity in atherosclerosis came from the observation that HLA-DR was abundantly expressed in both immune and vascular cells of human atherosclerotic lesions 1 . In the late 1980s, researchers reported that low-density lipoproteins (LDL) undergo oxidative modification in vivo and incite the generation of autoantibodies to modified LDL 2 . This was followed in the mid 1990s by the discovery that CD4 + T lymphocytes from human atherosclerotic lesions recognize LDL-derived antigen in an HLA-DR-dependent manner 3 and by the identification of vascular dendritic cells (DCs) in human aortic intima 4 .
These seminal studies generated great interest in the immune mechanisms of atherosclerosis and were followed by 2 decades of intensive research into the roles of adaptive immune responses in disease initiation and progression. The studies defined the distinct roles of T lymphocyte subsets in the disease process 5 : Th1-biased responses promote atherosclerosis whereas Tregs play a major counter-regulatory role and limit lesion inflammation and development, in part through the anti-atherogenic roles of IL-10 and TGF- [5] [6] [7] . Until recently, however, only a few studies addressed the contribution of DCs to the immune responses of atherosclerosis.
DCs are detected in normal vessels 8, 9 preferentially in regions predisposed to atherosclerosis 8 where they accumulate lipid and contribute to the development of early fatty streaks 10 . Besides these lipid scavenging properties, investigators have recently interrogated the roles of DCs in shaping atherosclerotic immune responses. DCs from normal and atherosclerotic vessels are able to process and present model antigens to CD4 + T cells in an MHCII-dependent manner 9, 11, 12 . Adventitial DCs, like spleen and lymph node DCs, engage in sustained interactions with T cells, leading to T cell proliferation and cytokine secretion 11 . However, the outcome of these interactions between conventional DCs (cDCs) and T cells on atherosclerosis is were followed by 2 decades of intensive research into the roles of adaptive imm mu u une e e re esp sp pon on onse se ses s in disease initiation and progression. The studies defined the distinct roles of T lymphocyte subsets n n t the he he d d di is isea ea ease se e pro ro oc ce ces ss 5 : Th1-biased responses p pro ro rom m mote atheroscle e ero r r si is s w wh whereas Tregs play a m maj jo or counter-r-re re egu u ula ato tory ry y r r rol ol ole e e an and d d li li imi mi it l lesio on on infl fl la am mma ma mati tion on n a a and nd d dev evel el lop op opme me ent nt nt, , in in p p par ar art t th t t ro ro roug ug gh h h the an nti ti ti-a -a -ath th ther erog og oge en enic ic ro ol oles es of f f IL IL-1 1 10 0 an an and d d G TG TGF-F-- 5 5 5-7 . Un Un Unti il l l re e ece e ent nt ntl ly ly, , ho ho h we we eve ve v r, r r, o o onl nly y y a a fe fe f w w w s st stud d die e es s addressed th h he e e co co cont nt ntri ri ribu bu buti ti ion on o o of f f D DCs Cs Cs t t to o o th h he e e im im immu mu mune ne ne r r res es espo po p ns ns nses es es o o of f f at at athe he ero ro rosc sc scle le lero ro rosi si s s. s. . f f f still unclear. For example, genetic manipulations to expand or deplete the general pool of cDCs (and CD11c-expressing macrophages) using the CD11c-diptheria toxin receptor mouse did not reduce the development or progression of atherosclerosis 13 . This disappointing and unexpected finding could be attributed either to a dominant role of cDCs in the modulation of cholesterol homeostasis or to the critical role of cDCs in the control of steady-state myelogenesis 14 , blurring any potential role of DCs in adaptive immune responses to atherogenic stimuli.
A few studies addressed the role of a distinct DC subset, plasmacytoid DCs (pDCs), in atherosclerosis. pDCs originate in the bone marrow, circulate in the blood and home to secondary lymphoid organs as well as sites of inflammation. pDCs are specialized type I interferon (IFNs) producers in response to virus infection and as such are major players in innate immune responses 15, 16 . As the name suggests, pDCs are also capable of antigen presentation to T cells 17, 18 , a function shown to be critical in some autoimmune disease models 19 , although not in viral infection responses 20 . pDCs are detected in normal and atherosclerotic vessels, both in humans and mice [21] [22] [23] . Reduced blood levels of pDCs in humans are suggested to reflect increased plaque infiltration and correlate with coronary artery disease 24, 25 . Vascular pDCs are able to present antigen to T cells in vitro 23 and can load a model peptide on MHCII in vivo 26 .
However, the outcome and relevance to atherosclerosis remains uncertain. While some studies suggested a pro-atherogenic role for pDCs 23, 26 , other investigators reported an athero-protective effect 22 . The reasons for these discrepancies remain unknown and the mechanisms through which pDCs alter immune responses in atherosclerosis remain elusive. In particular, each of the above-mentioned atherosclerosis studies used antibody-mediated depletion of pDCs targeting PDCA1 (BST-2/CD317), which is not entirely specific for pDCs 27 , especially in inflammatory settings. Therefore, alternative approaches are required to definitively address the role of pDCs nterferon (IFNs) producers in response to virus infection and as such are major p p play ay yer r rs s s in in in i i inn nn n a ate mmune responses 15, 16 . As the name suggests, pDCs are also capable of antigen presentation to T ce ce ell ll lls s s 17, 17, 17, 18 18 18 , , a a a fu unc nc ncti tion shown to be critical in som om ome e e autoimmune d d disea ease se se models 19 , although not n n v v vir iral infecti ion on n res espo po ons ns ses es es 20 20 0 . . pD pDCs Cs Cs a are re detec ected in n n no or orm ma mal l l a and nd a at th her e o os sc cl ler ero ot oti ic ic v ve e esse se sels l ls, bo bo both h th i in n n hu huma ma mans ns n a and nd nd m m mic ice e 2 21-21-23 23 . R Re Redu duc ce c d d d bl bl bloo o ood d le e eve ve vel ls ls o o of f f p pD pDCs Cs in n n h h hum um uman an a s s s ar ar are e e su su ugg gg ges es ste te t d d d to to o r r re e efle e ect t t ncreased plaq aq aque ue ue i i inf nf nfil i tr tr t at a a io o on n n an a a d d d co co c rr rr rrel l lat at a e e e wi wi w th th th c cor or oron on nar ary y y ar ar arte te tery ry ry d d dis i ea ea ease se se 24 24 24, 25 25 25 . . Va Va Vasc sc scul ul ular ar a pDCs are and the mechanisms through which they modulate immune-mediated diseases. Here, we used selective genetic approaches to interrogate the role of pDCs in the development of murine atherosclerosis. We identify a critical role for MHCII expression on pDCs in driving proatherogenic T cell immunity. The results may have broad implications for the understanding of the immune mechanisms of atherosclerosis and other related immune diseases.
Methods
An expanded methods section is available in the online supplementary material.
Mice
All experiments were approved by the Home Office, UK. pIII+IV -/-mice were previously described 28 .
Flow cytometry
Single cell suspensions were stained with fluorophore-conjugated antibodies (Supplemental Table 1 ) and analyzed using LSRII Fortessa (BD) or CyAN ADP (Beckman Coulter) flow cytometers using the gatings shown in Supplemental Figure 1 .
Analysis of in vivo antigen presentation
The E -GFP/Y-Ae system was described previously 26 . To determine the anatomical location of the antigen processing pDCs, Ldlr -/-mice were injected with DQ-OVA. After 1 h the aortic sinus was harvested for immunohistochemical analysis. For in vivo OT-II stimulation, C57BL6 mice were injected with CFSE -labeled OT-II T cells, then injected with ovalbumin-loaded pDCs.
OT-II T cell proliferation was assessed after 3 days by flow cytometry.
In vitro dendritic cell culture
Bone marrow (BM) pDCs or spleen CD11c + cells were isolated using an AutoMACS Pro All experiments were approved by the Home Office, UK. pIII+ I I IV + -/-V V mice were p pr r revi vi v ou u usl sl sly y y -described 28 .
Fl low ow ow c c cyt yt ytom om ome e etry y y S S Sing g gle cell susp spe e ens s sion on ns we we were re re s s st ta tain in ned ed ed w w wit th h fl luo uo uorop ph ho o ore---c co onj nj jug ug gat ate ed ed ant ntib ib ibo od die ie es s ( ( (Su Sup pp pple le leme me ment n nta al a Ta Ta abl separator. Supplemental Figure 2 shows pDC purity. For cytokine production, purified pDCs were treated with CpG oligonucleotides or control GpC. For antigen presentation assays, DCs were preincubated with antigen (OVA or native LDL) then with antigen-specific T cells. T cell activation was measured by proliferation or Il-2 production.
Statistics
Results were presented as mean ± S.E. They were analyzed in GraphPad Prism (La Jolla, CA, USA) using unpaired t-test, non-parametric Mann-Whitney U test, one way analysis of variance or repeated measures two-way analysis of variance, as appropriate. P value (two-sided) of <0.05
was considered significant. Figure 3B-3D ). Of note, contrary to the phenotype of cDC-less mice 14 , blockade of pDC development did not alter myelogenesis, despite chronic feeding with a HFD (Supplemental Figure 3D) . We also assessed the numbers of other DC subtypes. As previously reported for Tcf4-cKO mice 29 or Apoe -/-mice 13 , suggesting a similar potential role for pDCs in cholesterol metabolism.
Results

Selective blockade of pDC development limits atherosclerosis in
Previously, increased cholesterol in cDC-depleted mice was proposed to explain the lack of effect of cDC depletion on atherosclerosis 13 . It is therefore remarkable that despite higher plasma cholesterol levels, pDC-less Ldlr -/-Tcf4-cKO mice showed significantly reduced atherosclerosis compared with Ldlr -/-Tcf4-WT controls ( Figure 1E ). Reduced lesion compared with controls ( Figure 1C ). The proportions of CD11b + and CD8 + cel ells l ls w w wit it th hi hin n n th th this i is population were not significantly changed (data not shown). Loss of pDCs and increase of cDCs f ma may y y ha ha have ve e e eff ff ffe ects ts s o o on n regulatory T cells. Howeve er r r w we e found no diff ff fer e en nce ce ces s in the levels of spleen 
MHCII-restricted antigen presentation to T cells by pDCs.
We next addressed the potential functions of pDCs that may be influencing atherosclerosis. In general, pDCs have so far been found to be less potent stimulators of CD4 + T cells in the presence of cognate antigen than cDCs or inflammatory/bone-marrow derived DCs.
Nevertheless, pDCs are capable of antigen presentation in a number of conditions 19, 26, 30 . We 
MHCII-restricted presentation of native LDL to T cells by pDCs.
To investigate an antigen with relevance to atherosclerosis, we utilized a T cell hybridoma specific for human native LDL (nLDL) cloned from hApoB100tg x Ldlr -/-mice, originally 
MHCII expression on pDCs promotes atherogenesis.
We therefore examined the role of selective deletion of MHCII in pDCs on the adaptive immune response to HFD and its consequence on the development of atherosclerosis. Lethally irradiated (Fig gu ur r re 2G G) ). Imp mp m or or rta a ant ntly ly y, pD DC C Cs sti timu mu m la late te ed d nL nL n DL DL Lp pec ec cif if fic ic ic T T T c c cel el ells ls t t to o th th t e e sa sa ame me m e ex xt x en en nt t t a as as c cDC DC DCs s s ( ( (Fi Fi igu gu gure re re 2 2G G G), ) , s s sug ug u ge ge gest st tin n ng g g an an n e enh nh n an an ance ce ced d d ab ab abil ilit it ity y to to present this t t typ yp ype e e of of of a a ant nt ntig ig gen en n c c com om ompa pa pare re ed d to to to t t the he he m m mod od odel el el a a ant n n ig ig gen en en O O OVA VA VA (Fi Fi Figu gu gure re re 2 2 2C C C). ). . T T The he he r r res e e ults /-and MT:pIII+IV
Ldlr
-/-mice, respectively, p=0.82) were similar between groups.
Numbers of blood monocytes and neutrophils were also comparable between the 2 groups of mice (Supplemental Figure 5A) . Unlike Tcf4-cKO mice, pIII+IV deletion had no effect on the distribution of pDCs ( Figure 3A) or cDCs ( Figure 3B) . However, MT:pIII+IV
mice displayed a selective abrogation of MHCII expression on pDCs ( Figure 3C ). MHCII expression on cDCs was unaltered (Supplemental Figure 5B ) and there were no differences in cDC activation markers including CD40, CD80 and CD86 between the 2 groups of mice (data not shown). Interestingly, aortic root lesion size was significantly reduced in MT:pIII+IV Figure 3E ). We therefore assessed the effect of this pDC-restricted MHCII deficiency on T cell responses. pIII+IV deletion had no impact on Tregs levels in the spleen and did not alter their suppressive potential (Supplemental Figures 5C and 5D ). However, we found a significant reduction of pro-atherogenic Ifn-producing CD4 + T cells (but no differences E E an and 5F 5F 5F). ). ) Imp mpor orta tant t ntly l ly, , th h ther ere e wa was s a a su subs bsta ta t nt nt tia ial l l de d decr crea ease se o of f f v vascular T (Figure 4A ), and T cell depletion was substantial in anti-CD4-treated mice ( Figure 4B ) and maintained throughout the experiment (data not shown). Animal weights were similar between groups ( Figure 4C ). pIII+IV deficiency had no effect on serum cholesterol, whereas CD4 + T cell depletion led to a 25% decrease (Figure 4D) (Figure 4E) , which is consistent with the phenotype of Rag1-deficient animals 31, 32 and the pro-atherogenic role of CD4 + T cells 33 Figure 6 ) and only pDCs were defective in MHCII expression (Figure 5A-C) . This pDC-specific MHCII deficiency again resulted in a Figure 4E ). The results strongly support an MHCII-CD4 + T cell dependent path th hwa wa way y y fo fo for r r th th the e e pr pr p o o atherogenic effect of pDCs.
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Discussion
Atherosclerosis development is driven by both innate and adaptive immune responses. Recent studies further highlighted the role played by LDL in driving antigen-specific pro-atherogenic T cell immunity 37 . T cell-mediated responses and disease severity were shown to be highly 41 . Ho owe we ev ve er, r w w wh he heth the e er t the hese se se d dis sti in nct ef f ffect t ts r requ qu qui ir ire e e an an nti ig ge en n pres es sen nta ta ati t tio on on b by y y D DC DC su ub ubse se ets s s e ema ma main in ns s s el el elus us usi iv ive. e. e. R R Red ed edu u ucti ti ion on o o of f f at the he her ro rosc sc cle le lero ro ros si sis in in in m m mic ic ce e e la la lack ck ckin in ing g g MH MH MHCI CI CII-I-I as asso so soci ci iat at ated ed ed i i inv n nvar ar aria iant nt nt c c ch ha hain in in CD74 42 is fr fr req eq eque ue uent nt ntly ly ly c c cit it i ed ed d a a as s s ev ev vid id den en ence e e f f for or or a a a po po pote te tent nt ntia ia ial l ro ro ole le le o o of f f an an anti ti t ge ge en n n pr pr pres es esen en enta ta ati ti tion on on i i in n n the antibody depletion strategy, used in all 3 previous studies that addressed the role of pDCs in atherosclerosis, we used genetically-modified mice with selective deficiency in pDCs. Our results clearly show that the development of atherosclerosis is reduced in pDC-less mice, which strongly argues in favor of a major role of pDC-mediated immunity in driving the atherogenic process.
A limitation of the depleting strategies mentioned above and the use of pDC-less mice is that they allow no conclusion about innate versus adaptive functions of pDCs in atherosclerosis.
Indeed, besides their major role in shaping innate immune responses, pDCs have also been suggested to function as antigen presenting cells (APCs). They are capable of antigen crosspresentation to CD8 + T cells 44, 45 , express MHCII molecules and acquire a mature phenotype to internalize, process and present antigen to CD4 + T cells 17, 18 . However, such APC function could not be observed in vivo using models of virus infection and antibody-mediated pDC depletion 46 .
It appears that under conditions of acute viral infection, pDCs mainly act via type I IFN presentation to CD8 + T cells 44, 45 , express MHCII molecules and acquire a matu ur r re p p phe he eno no noty ty type pe p t to nternalize, process and present antigen to CD4 + T cells 17, 18 . However, such APC function could no ot t be be be o o obs bs bser er e v v ved d in in in v vivo using models of virus inf nf nfec ec e t tion and antibo bo ody d -m -m me ed ediated pDC depletion 46 .
Our results might appear in contradiction with the tolerogenic role assigned to pDCs in other settings. However, previous studies on the role of pDCs in antigen-specific CD4 + T cell responses in vivo used a disease-unrelated model antigen, i.e. OVA 30 It should be noted that the present work addressed the role of pDCs in early atherosclerosis, at which point pro-atherogenic T cell immunity greatly influences atherosclerosis development in mice 32 . Additional studies are needed to determine the contribution of pDC-mediated immunity at later stages of disease development. Since pDCs and T cells infiltrate both early and advanced atherosclerotic lesions in humans 21-25, 47, 48 , we speculate that our results will also bear relevance to the human disease. However, direct testing mmunity. Finally, the outcome of antigen presentation by pDCs might depend on on n t t the he h n n nat at atur ur ure e e o of he presented antigen and the local microenvironment where presentation occurs. It It I i i is s s co co con nc nce ei eiva va vabl bl ble e e th th that at u un n nde e er b b ba a as s sal l l no no n n-n-in in infl flam am amma ma ato to tory ry ry c c con on ondi it t tio on ons, s, L LD DL D presentation b b by y y pD pD pDCs Cs C i ind n n uc uc uces es es t tol ol o er er e og og o en en enic ic c a a ada da dap p pti tive ve ve i i imm mm mmun un une e e re re resp sp spon on nse se ses, s, s w w whi hi hich ch c t t the he hen n n gr gr grad a ually of this hypothesis is still required.
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Cell preparation from aorta
Cell suspension from aorta was prepared by enzyme digestion as previously described 6, 7 . Briefly, Ldlr -/-mice were placed under terminal anesthesia and perfused with 2 mmol/L EDTA (Sigma-Aldrich, Gillingham, UK) in PBS via cardiac puncture to remove blood contamination from vascular tissue. After removal of aortas, a single cell suspension was obtained by incubation of aortic segments in an enzymatic suspension containing 450 U/mL collagenase type I, 125 U/mL collagenase type XI, 60 U/mL hyaluronidase, and 60 U/mL DNase (all from Sigma-Aldrich) in PBS containing 20 mmol/L Hepes at 37°C for 1 hour. Digested aortas were then mechanically disrupted through a 40-µmol/L cell strainer to release a single cell suspension. All the Abs used Sage et al, CIRCULATIONAHA-2014-011090-R2 for flow cytometry analysis of mouse aorta had been validated on cell suspensions from spleen/lymph nodes untreated or treated with the enzyme digestion cocktail.
Flow cytometry
Single cell suspensions of bone marrow, spleen, lymph node, blood and aorta were stained with fluorophoreconjugated antibodies (Supplemental Table 1 Figure 1 . In some experiments,
Siglec-H (Miltenyi) was used as an additional pDC marker.
Analysis of in vivo antigen uptake/processing
To study the ability of aortic pDCs to present systemic antigen, we used the Eα-GFP/Y-Ae system as described pDCs pre-incubated with ovalbumin (100 µg/ml) for 3h. OT-II T cell proliferation (CFSE dilution) was assessed after 3 days by flow cytometry in the popliteal lymph node, using spleen and the contralateral popliteal lymph node as internal controls.
In vitro dendritic cell culture
Bone marrow pDCs and spleen CD11c + cells were isolated by negative and positive magnetic selection, respectively, according to the manufacturer's instructions using an AutoMACS Pro separator (Miltenyi). For cytokine production, purified pDCs (2 x 10 4 ) were treated with type A or B CpG or control GpC oligonucleotides (10 µg/ml; Invivogen). IFNα levels in supernatants were quantified by ELISA (eBioscience).
Antigen-specific T cell stimulation in vitro
OT-II CD4 + T cells were incubated with cDCs or pDCs preincubated with 100 µg/ml ovalbumin (Sigma) and proliferation quantified after 3 days by 3 H thymidine incorporation over the final 18h. An I-A b restricted murine T cell hybridoma (48-5T) recognising human ApoB100 10 was added to pDCs or CD11c + cells preincubated for 4h with native human LDL (50 µg/ml; Intracel) in 0.5% serum-DMEM and incubated overnight. Supernatants were analysed for IL-2 levels by ELISA (Peprotech).
Analysis of atherosclerotic lesions
Total plasma cholesterol was quantified using a Cholesterol RTU kit (Biomerieux).
Aortic root atherosclerotic lesions were analysed by Oil Red O and CD3 staining as previously described 11 .
Images were captured and analysed using a Leica DM6000B microscope and accompanying software.
Statistics
Results were presented as mean ± S.E. They were analyzed in GraphPad Prism (La Jolla, CA, USA) using unpaired t-test, non-parametric Mann Whitney U test, one way analysis of variance or two-way analysis of variance, as appropriate. A P value (two-sided) of <0.05 was considered significant. For analysis of Sage et al, CIRCULATIONAHA-2014-011090-R2 atherosclerotic lesions in the aortic root, the entire 10-section profile was analyzed by repeated measures twoway analysis of variance and the p value for between groups displayed.
